Highlights Navidea Biopharmaceuticals, Inc.

Equities

NAVB

US63937X2027

Delayed OTC Markets Other stock markets 20:29:06 10/05/2024 BST			5-day change	1st Jan Change
0.036 ^USD	-5.26%		-6.01%	-34.78%

2023	Navidea Biopharmaceuticals, Inc. announced that it expects to receive $0.75 million in funding	CI
2023	Navidea Biopharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Navidea Biopharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-14	CI
Navidea Biopharmaceuticals Says NYSE American Panel Upheld Delisting Decision	06/10/23	MT
Navidea Biopharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	11/08/23	CI
Navidea Biopharmaceuticals Confirms Rejection of ProPhase Labs' Proposal to Buy Some of Its Assets	30/06/23	MT
ProPhase Labs Says Offer to Acquire Certain Navidea Biopharmaceuticals' Assets Rejected	29/06/23	MT
ProPhase Labs, Inc. cancelled the acquisition of Certain Assets from Navidea Biopharmaceuticals, Inc. for $7 million.	28/06/23	CI
Navidea Biopharmaceuticals Notified of Non-Compliance With NYSE American Listing Rule	05/06/23	MT
Navidea Biopharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	11/05/23	CI
Navidea Biopharmaceuticals, Meilleur Technologies Sign License Deal for Alzheimer's Disease Diagnosis Agent	14/04/23	MT
Navidea Biopharmaceuticals, Inc. Enters Asset Purchase Agreement with Meilleur Technologies, Inc. for Rights to NAV4694	13/04/23	CI
Navidea Biopharmaceuticals, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2022	21/03/23	CI
Navidea Biopharmaceuticals, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2022	21/03/23	CI
Navidea Biopharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	21/03/23	CI
Navidea Biopharmaceuticals Announces the Notice of Allowance for U.S. Patent Application for Key Component of the Cancer Immunotherapy Pipeline	03/01/23	CI
Navidea Biopharmaceuticals, Inc. Announces 50th Participant Enrolled in the its Phase 3 Trial in Rheumatoid Arthritis	28/11/22	CI
Navidea Biopharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	14/11/22	CI
Navidea Biopharmaceuticals Tapped for Presentation at November Cancer Conference	05/10/22	MT
Navidea Biopharmaceuticals, Inc. Announces Results from the Completed NAV3-31 Phase 2B Clinical Study as Well as the Preliminary Results of Its Ongoing NAV3-32 Phase 2B Study At Annual Meeting of the American College of Rheumatology	15/09/22	CI
Navidea Biopharmaceuticals, Inc. Opens Nine New Sites in Its Pivotal Phase 3 Trial in Rheumatoid Arthritis	02/09/22	CI
Navidea Biopharmaceuticals, Inc. Terminates Memorandum of Understanding with Jubilant Radiopharma	02/09/22	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Navidea Biopharmaceuticals, Inc.

Equities

NAVB

US63937X2027

Highlights

Filters